Gastroesophageal cancer
MONDO:0850129A gastrointestinal system cancer that is located in the proximal esophagus and the distal stomach.
3001 clinical trials for this condition and its sub-types, 157 tagged with Gastroesophageal cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New drug combos aim to boost survival in Hard-to-Treat cancers
Disease control Stopped earlyThis study tested several immunotherapy-based drug combinations in 214 people with advanced stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery or had spread. Participants received either standard chemotherapy or chemotherapy plus the imm…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for stomach cancer: targeted drug combo enters human trials
Disease control Stopped earlyThis study tests a new drug called bemarituzumab, given together with chemotherapy and an immunotherapy drug (nivolumab), in 72 adults with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The main goals are to check safety and see if the co…
Phase 1/2 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New cancer drug trial halted early – what we know
Disease control Stopped earlyThis early-phase trial tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, breast, lung, and other cancers. The study aimed to check safety and see if the drug could shrink tumors. However, the trial was terminated early, so f…
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Stomach cancer combo study halted early
Disease control Stopped earlyThis study tested several drug combinations in 40 people with advanced stomach or gastroesophageal junction cancer that had not been treated before. The goal was to see which combinations shrank tumors. The study was terminated early, so results are limited.
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Early trial of experimental cancer combo halted after 21 patients
Disease control Stopped earlyThis early-stage study tested an experimental oral drug (PF-07265028) alone or combined with an immunotherapy injection (sasanlimab) in 21 people with advanced solid tumors, including stomach, lung, and head/neck cancers. The main goals were to find a safe dose and check for side…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Stomach cancer drug combo trial halted midway
Disease control Stopped earlyThis study tested a new drug called DKN-01 combined with tislelizumab and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that could not be removed by surgery. The trial enrolled 247 adults who had not received prior treatment or whose cancer had…
Phase 2 • Sponsor: Leap Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Cancer drug trial halted early – what happened?
Disease control Stopped earlyThis phase 2 trial tested the drug futibatinib in 115 people with advanced solid tumors or blood cancers that have specific FGFR gene changes. The goal was to see if the drug could shrink tumors or cause remission. The study was terminated early, so final results are not yet clea…
Phase 2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Experimental cancer combo trial halted early – what it means for patients
Disease control Stopped earlyThis early-stage trial tested a new drug called BDC-1001, alone or with the immunotherapy nivolumab, in 175 people with advanced HER2-positive cancers (like breast, colorectal, and stomach cancers) that had stopped responding to other treatments. The study aimed to check safety a…
Phase 1/2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:13 UTC